Basket | Login


AMYPAD project progresses to second stage of applications for IMI2 Call 5

Thursday 17 December 2015

After a positive evaluation of its first stage application, the Amyloid imaging to Prevent Alzheimer’s Disease (AMYPAD) project consortium has been officially selected to develop a second stage application, together with its European Federation of Pharmaceutical Industries and Associations (EFPIA) partners.

The project aims to:

1)    improve the diagnostic workup of patients suspected to have AD and their management;

2)    understand the natural history of AD in a pre-symptomatic stage in order to better select patients for trials; And

3)    monitor change in β-amyloid deposition to quantify the impact of novel therapies. 

AMYPAD will address the above goals in close collaboration with already-up-and-running IMI project, EPAD (European Prevention of Alzheimer’s Disease). The Project coordinator is Amsterdam-based university, Stichting VU-VUmc. Alzheimer Europe would co-lead the work package dedicated to communication and dissemination.

The AMYPAD consortium’s short proposal (SP) was submitted under IMI2 Call 5 Topic 4:  “Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)”.